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Abstract 24 
Polygenic profiling has been proposed for elite endurance performance, using an additive 25 
model determining the proportion of optimal alleles in endurance athletes. To investigate 26 
this model’s utility for elite triathletes, we genotyped seven polymorphisms previously 27 
associated with an endurance polygenic profile (ACE Ins/Del, ACTN3 Arg577Ter, 28 
AMPD1 Gln12Ter, CKMM 1170bp/985+185bp, HFE His63Asp, GDF8 Lys153Arg and 29 
PPARGC1A Gly482Ser) in a cohort of 196 elite athletes who participated in the 2008 30 
Kona Ironman championship triathlon. Mean performance time (PT) was not 31 
significantly different in individual marker analysis. Age, sex, and continent of origin had 32 
a significant influence on PT and were adjusted for. Only the AMPD1 endurance-optimal 33 
Gln allele was found to be significantly associated with an improvement in PT (model 34 
p=5.79 x 10-17, AMPD1 genotype p=0.01). Individual genotypes were combined into a 35 
total genotype score (TGS); TGS distribution ranged from 28.6 to 92.9, concordant with 36 
prior studies in endurance athletes (mean±SD: 60.75±12.95). TGS distribution was 37 
shifted toward higher TGS in the top 10% of athletes, though the mean TGS was not 38 
significantly different (p=0.164) and not significantly associated with PT even when 39 
adjusted for age, sex, and origin. Receiver operating characteristic curve analysis 40 
determined that TGS alone could not significantly predict athlete finishing time with 41 
discriminating sensitivity and specificity for three outcomes (less than median PT, less 42 
than mean PT, or in the top 10%), though models with the age, sex, continent of origin, 43 
and either TGS or AMPD1 genotype could. These results suggest three things: that more 44 
sophisticated genetic models may be necessary to accurately predict athlete finishing time 45 
in endurance events; that non-genetic factors such as training are hugely influential and 46 
should be included in genetic analyses to prevent confounding; and that large 47 
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collaborations may be necessary to obtain sufficient sample sizes for powerful and 48 
complex analyses of endurance performance. 49 
 50 
Abbreviations 51 
ACE, angiotensin-converting enzyme; ACTN3, alpha-actinin-3; AGE, agarose gel 52 
electrophoresis; AMPD1, adenosine monophosphate deaminase 1; AUC, area under the 53 
curve; BDKRB2, bradykinin receptor B2; CKMM, creatine kinase-MM; FPR, false 54 
positive rate; GDF8, growth differentiation factor 8 (also known as MSTN or myostatin); 55 
GLUT4, glucose transporter type 4; HFE, high iron Fe, more commonly known as 56 
Human hemochromatosis gene; HIT, high-intensity interval training; HREC, Human 57 
Research Ethics Committee; HRM, high resolution melt; HWE, Hardy-Weinberg 58 
Equilibrium; NOS3, nitric oxide synthase 3; PPARGC1A, peroxisome proliferator-59 
activated receptor gamma, coactivator 1 alpha; RFLP, restriction fragment length 60 
polymorphism; ROC, receiver operating characteristic; TGS, total genotype score; TPR, 61 
true positive rate.                   .              62 
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Introduction 63 
The ability of sport scientists to predict which athletes amongst an elite group will 64 
become world-class is limited because the interactions between biological factors, 65 
training, recovery and competitive performance are not fully understood [1]. Human 66 
physical performance depends on environmental factors such as physical training, 67 
nutrition and technological support, as well as on genetic factors such as blood lactate 68 
threshold, maximal oxygen uptake (VO2max), glucose/lipid metabolism, and muscular 69 
strength [2]. Over 150 DNA polymorphisms have been associated with some form of 70 
human physical performance [3]. Many of these studies have only investigated individual 71 
polymorphisms or genes; however, despite the number of genes being investigated and 72 
associated with elite endurance performance, the achievement of elite endurance 73 
performance by a relatively small number of athletes is more than likely influenced by a 74 
combination of favourable genetic alleles. 75 
 76 
Recent studies [4-7] have proposed or utilised polygenic profiles for elite athletic 77 
performance, using a model originally outlined by Williams and Folland (2008) for 78 
optimal endurance performance [3]. While Williams and Folland’s original model 79 
contained 23 genetic polymorphisms associated with endurance performance, later 80 
models focused on smaller numbers of more strongly associated polymorphisms for 81 
endurance (seven to ten) [4, 5]. In order for comparability between models with different 82 
numbers of polymorphisms, the total genotype score (TGS) calculated generally 83 
represents the percentage of ‘optimal’ alleles for a particular phenotype. These models 84 
have been tested with other phenotypes such as success in a sporting field (in terms of the 85 
number of medals won or ranking in World and/or National Championships) [7, 8] and 86 
models with alternative polymorphisms have been proposed for speed/power  87 
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performance [6, 9], mitochondrial biogenesis specific endurance models [10], and even 88 
disease/health risk models [11]. While sporting success has been previously evaluated in 89 
terms of numbers of medals won [7] or ranking in different world championship events 90 
[8], no current study has examined athlete performance within a single sporting event. 91 
However, while associations of polygenic profile polymorphisms have been well 92 
established in endurance versus power athletes, or athletes versus non-athletes, the 93 
influence of these polymorphisms on performance success within a single race event has 94 
not yet been assessed.  95 
 96 
In this study we therefore  investigate the utility of the seven-marker optimal endurance 97 
model [5] to distinguish more successful athletes (faster performance time) from less 98 
successful athletes (slower performance time) in a cohort of 196 elite endurance athletes 99 
who participated in the 2008 Kona Ironman World Championship triathlon. This cohort 100 
was initially collected in 2008 and the association of ACTN3 Arg577Ter polymorphism 101 
analysed in this cohort in a prior study [12]. These race participants represent athletes 102 
with an extremely high level of endurance ability and present a valuable opportunity to 103 
investigate genetic endurance polymorphisms in relation to elite endurance athlete race 104 
performance. Despite the fact that participants can be classified into ‘faster’ and ‘slower’ 105 
groups based on their performance in the 2008 Kona Ironman, all qualifying athletes can 106 
be considered among the elite of worldwide endurance triathletes as the event is 107 
considered one of the most extreme endurance events in the world due to the strict 108 
qualifying requirements and the severe environmental conditions encountered during the 109 
‘ultra’ distance race.  110 
 111 
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This study investigated whether the seven polymorphisms strongly associated with an 112 
endurance polygenic profile as described in Ruiz et al. 2009 [5]—ACE Ins/Del, ACTN3 113 
Arg577Ter, AMPD1 Gln12Ter, CKMM 1170 bp/985+185bp, HFE His63Asp, GDF8 114 
Lys153Arg and PPARGC1A Gly482Ser—were individually associated with performance 115 
time (both unadjusted and adjusted for significant demographic variables) or whether the 116 
combined influence of these polymorphisms as a total genotype score (TGS) could 117 
distinguish ‘faster’ from ‘slower’ performance time of the Ironman athletes. Each of the 118 
genes included in Ruiz et al.’s profile is a strong candidate for involvement in endurance 119 
performance and has been found to be associated previously with improvements in 120 
physical ability. The functions of these seven genes and the impact of the profile 121 
polymorphisms on gene function are outlined below. 122 
 123 
ACE Ins/Del (rs4340) 124 
The ACE 287bp Ins/Del polymorphism (I/D; rs4340) is located in intron 16 of the gene 125 
angiotensin converting enzyme (ACE), which is heavily involved in the cardiovascular 126 
system, in particular with blood pressure regulation. The ACE gene encodes a zinc 127 
metallo-carboxypeptidase that converts the inactive angiotensin I peptide into the potent 128 
vasoconstrictor angiotensin II [13, 14], which is the end product of the renin-angiotensin 129 
system (RAS) for the regulation of blood pressure. It also contributes to the regulation of 130 
blood pressure through the kinin-kallikrein system by degradation of bradykinin, a strong 131 
vasodilator [14], and is also thought to be important for muscle development due to the 132 
fact that angiotension II stimulates growth of endothelial, cardiac, and smooth muscle 133 
cells [5, 15]. The presence of the 287bp insertion (I allele) in the ACE gene is associated 134 
with lower levels of ACE activity in serum and tissues, with the II genotype carriers 135 
having about half the activity level of DD carriers, while ID carriers have intermediate 136 
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levels [14]. The higher level of ACE activity for D allele carriers results in an increase in 137 
both angiotensin II and an increase in the metabolism of bradykinin, which, in addition to 138 
blood pressure regulation, has a significant impact on metabolic processes including 139 
uptake of glucose [15]. The D allele has also been shown to be associated with increased 140 
left ventricular hypertrophy [14] and some studies show an association with increased 141 
grip strength [9], indicating that the DD genotype may possibly be more beneficial for 142 
power sports or strength-trained athletes. Conversely, the II genotype has been found to 143 
be strongly associated with various types of endurance athletes [14, 15], and is one of the 144 
most strongly replicated associations in endurance athletes.  145 
 146 
ACTN3 R577X (rs1815739) 147 
The ACTN3 gene encodes α-actinin-3, which is a tissue-specific actin-binding protein 148 
expressed in skeletal muscle fibers to assist in anchoring actin filaments of the sarcomere 149 
during muscle contractions. Although both α-actinin-3 and highly similar protein α-150 
actinin-2 are both expressed in muscle, α-actinin-3 is only expressed in type II (fast-151 
twitch, anaerobic/glycolytic) muscle fibers, which have an increased contraction speed 152 
and contraction force compared to type I (slow-twitch, oxidative) fibers [12]. The ACTN3 153 
Arg577Ter nonsense mutation (R577X; rs1815739) results in a truncated and non-154 
functional protein which subsequently results in α-actinin-3 deficiency, and has been 155 
shown in knockout mouse models to decrease muscle strength and contraction force due 156 
to a decrease in the size of type II fibers. Presence of the R allele is therefore thought to 157 
improve strength and speed of contraction and has been shown to be significantly more 158 
common in sprinting athletes [9]. It has also been shown that the X allele, which results 159 
in the α-actinin-3 deficiency, shifts the type II fibers energy generation from their usual 160 
anaerobic processes to aerobic, oxidative processes, increasing the fatigue-resistance of 161 
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the fibers [12]. While this suggests that the X allele may be advantageous for endurance, 162 
at a cost to speed and strength, association studies in endurance athletes have had mixed 163 
results [9]. Nevertheless, this polymorphism has a clear, replicable effect on strength and 164 
speed, and has thus been included in every profile on athletic performance. 165 
 166 
AMPD1 Q12X (rs17602729) 167 
The AMPD1 Gln12Ter polymorphism (Q12X; rs17602729), also known as the C34T 168 
polymorphism, is located in the muscle-specific isoform of the AMP deaminase gene 169 
(AMPD1), which deaminates the adenosine monophosphate (AMP) that accumulates 170 
during exercise into inosine monophosphate (IMP) as part of the purine nucleotide cycle 171 
[16, 17]. An accumulation of AMP results in loss of AMP and an increase of adenosine in 172 
the tissues, which results in decreased alertness and lower time to fatigue. AMPD1 thus 173 
assists in salvaging adenosine molecules and helping regulate the levels of IMP, AMP, 174 
adenosine diphosphate (ADP), and adenosine triphosphate (ATP) in skeletal muscles 175 
during exercise [5]. Additionally, the AMPD1 enzyme helps promote the generation of 176 
ATP from ADP by the enzyme myokinase by altering the reaction equilibrium [17], and 177 
is therefore extremely important in determining the energy availability to skeletal 178 
muscles during exercise. The substitution of a T nucleotide for a C at position 34 results 179 
in a nonsense mutation whereby a glutamine is converted to a stop codon, resulting in a 180 
truncated non-functional protein, and therefore resulting in AMPD1-deficiency. The lack 181 
of AMPD1 enzyme has been associated with an increased frequency of mild forms of 182 
myopathy post-exercise, with lower time to fatigue and muscle cramping [16], though not 183 
all individuals with AMPD1 deficiency will experience these symptoms [17].  Although 184 
the deficiency of AMPD1 was originally expected to predominantly affect short-term 185 
exercise, and although it has been associated with a lower mean anaerobic power and 186 
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faster decline in power output [18], the X allele resulting in AMPD1 deficiency has been 187 
found to be about half the frequency in endurance athletes compared to controls [17]. It 188 
has since been suggested by studies examining accumulation of IMP and AMP during 189 
exercise that at the end of long endurance events when energy stores are depleted, an 190 
accumulation of AMP occurs which is necessarily converted to IMP by AMPD1 enzyme 191 
[17]. The Q allele is thus associated with an advantage for endurance performance while 192 
X allele carriers may be disadvantaged by early AMP accumulation and fatigue.  193 
 194 
CKMM 3’ UTR NcoI RFLP (rs8111989) 195 
The gene CKMM contains a NcoI RFLP in the 3’ untranslated region of the gene (3’ UTR  196 
NcoI RFLP, rs8111989), resulting in two alleles named for their fragment lengths, the 197 
more common 985+185bp allele and the rarer 1170 bp allele [19], which correspond to a 198 
T to C single nucleotide substitution, respectively. The CKMM gene is a muscle-specific 199 
form of creatine kinase (CK) which catalyses the conversion of phospho-creatine (PCr) 200 
and ADP into creatine and ATP, as well as the reverse reaction. This CK/PCr energy 201 
buffering system acts as a temporal buffer for energy by ensuring that ATP can be 202 
quickly generated from cellular stores of ADP when required [5, 19]. It also acts as an 203 
energy ‘shuttle’ between subcellular locations. The activity of CKMM in catalysing the 204 
reaction therefore can impact on ATP availability to the muscle, which may limit 205 
performance. In fact, type I (slow twitch, oxidative) muscle fibers have been reported to 206 
show a two-fold lower CK activity compared to type II (fast-twitch, glycolytic) muscle 207 
fibers [19]. Although the NcoI RFLP is located in the 3’ UTR and thus does not result in 208 
a functional change in the CKMM protein, deletion of the CKMM 3’ UTR results in a 209 
change to the mRNA cellular localisation signal, which is important for correct CK/PCR 210 
shuttling [20] and which may possibly result in altered expression levels of CKMM due to 211 
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mRNA instability [21]. Though the mechanisms by which this may affect performance 212 
are still not clear, it has been shown through performance studies that the CC genotype 213 
(1170bp/1170bp) results in a lower change in VO2max (ml / kg • min) in response to 214 
endurance training, while the TT genotype results in 1.5- to 3-fold higher change in 215 
VO2max [19]. This suggests that the T allele (985+185bp) may be beneficial for endurance 216 
performance [5]. The TT genotype has also been associated with an increased likelihood 217 
of extremely high blood CK levels post-exercise which may indicate damage to skeletal 218 
muscle [21] and therefore may also be involved in exercise tolerance.  219 
 220 
GDF8 K153R (rs1805086) 221 
The GDF8 Lys153Arg polymorphism (K153R; rs1805086) is located in exon 2 of the 222 
growth differentiation factor 8 gene (GDF8), which is more commonly known as 223 
myostatin (abbreviation MSTN). Myostatin functions as a negative regulator of myoblast 224 
differentiation into muscle fibers, by signaling to increase p21, resulting in the inhibition 225 
of Cdk2 and thus the hyperphosphorylation of retinoblastoma (Rb), which then promotes 226 
cell cycle progression and thus myoblast proliferation [22, 23]. It is therefore a key factor 227 
in the determination of both the number and size of muscle fibers [22, 23], and 228 
myostatin-deficient animals, whether due to knockout, as in mouse models, or naturally 229 
deficient, as in cattle showing the ‘double-muscle’ phenotype, have been well established 230 
to exhibit up to three times as much muscle mass as wildtype [22]. Myostatin deficiency 231 
has been demonstrated to result in a similar hypertrophy of skeletal muscle in rare human 232 
cases also [24]; however, the K153R SNP, more common in humans than recessive 233 
homozygous myostatin deficiency, has also been shown to result in significant increases 234 
in skeletal muscle mass and strength for the RR genotype [23], thought to be due to 235 
alteration in binding affinity resulting in a less effective inhibition of myoblast 236 
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proliferation. Its clear importance for the determination of muscle mass and strength 237 
make this marker a strong candidate for any polygenic profile of athletic performance. 238 
 239 
HFE H63D (rs1799945) 240 
The HFE His63Asp polymorphism (H63D; rs1799945) is located in the hereditary 241 
haemochromatosis gene (HFE; standing for High Fe) which is a transmembrane protein 242 
with a key role in regulating iron absorption. The HFE protein is thought to regulate the 243 
interaction of other key molecules involved in iron uptake and circulation [25],  including 244 
transferrin, a plasma protein that binds absorbed iron for circulation; the transferrin 245 
receptor (TfR, encoded by TFRC and TRF2 genes), a transmembrane glycoprotein 246 
facilitating intake of transferrin-bound iron into cells; ferroportin (FPN1 or SLC40A1), a 247 
transmembrane protein located on the basolateral surface of gut cells macrophages, which 248 
allows transport of absorbed iron out of cells into circulation; and hepcidin (HAMP), a 249 
negative regulator of iron transport that competitively binds ferroportin, preventing 250 
release of iron from cells. HFE primarily interacts with TfR by decreasing the affinity of 251 
transferrin for the TfR, thus reducing the uptake of transferring-bound iron [26, 27] as 252 
well as possibly influencing regulation of hepcidin levels, with decreases in hepcidin 253 
levels reducing the negative inhibition of ferroportin and thus increasing export for iron 254 
from gut cells into circulation and tissues [25, 28]. The H63D polymorphism has been 255 
shown to reduce the ability of the HFE protein to bind to its ligand, thereby preventing 256 
the inhibition of transferrin-TfR binding and resulting in increased transport of iron into 257 
circulation and cells [26, 27, 29]. This results in an increased level of iron, as measured 258 
by transferrin saturation (TS, or percentage of TfR bound to transferrin), serum ferritin 259 
concentration (SF, the acute-phase storage molecule for iron) [25, 29], even in the 260 
absence of additional mutations in HFE and the other key iron transport genes TRF2, 261 
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FPN1, and HAMP [29]. As endurance athletes require reasonable iron levels to improve 262 
their oxygen-carrying capacity, any impairments to the iron transport mechanisms that 263 
result in a decreased level of iron, even if not at anaemic levels, may result in a poorer 264 
aerobic capacity, possibly through oxidative enzyme and respiratory protein activity [30]. 265 
Alternatively, the H63D polymorphism, by resulting in hyperferritinaemia, may have the 266 
potential to boost aerobic capacity in athletes, and indeed the D allele has been found to 267 
be at a significantly higher frequency in endurance cyclists and Olympic-class endurance 268 
runners compared to sedentary population controls [31], despite the fact that some studies 269 
have not found a significant impact on VO2max from HFE mutations [31, 32]. The 270 
increased frequency of D allele (specifically heterozygotes) in endurance athletes 271 
therefore supports its inclusion in a polygenic model; however, due to the fact that a 272 
homozygous DD genotype may increase iron levels adversely, leading to symptoms of 273 
iron overload such as iron deposition in abdominal organs and cardiac tissue [27, 33], the 274 
heterozygous HD carrier may have the better endurance advantage, leading to its optimal 275 
weighting in Ruiz et al.’s polygenic profile [5].   276 
 277 
PPARGC1A G482S (rs8192678) 278 
The PPARGC1A Gly482Ser polymorphism (G482S; rs8192678) is located in the 279 
peroxisome proliferator-activated receptor-γ coactivator-1α gene (PPARGC1A), which is 280 
a coactivator of regulatory genes for the oxidative phosphorylation (OXPHOS) pathway 281 
for generation of ATP. As endurance athletes predominantly utilise aerobic energy 282 
generation through oxidative phosphorylation, requiring higher maximal oxygen uptakes 283 
(VO2max) compared to sprint and power sports, the PPARGC1A gene could potentially 284 
impact on energy availability [34]. However, PPARGC1A is also involved in the 285 
activation of other pathways which may also equally be important for endurance athletes, 286 
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including stimulating mitochondrial biogenesis through binding with nuclear respiratory 287 
factors NRF-1 and NRF-2 and mitochondrial transcription factors [34, 35]. PPARGC1A 288 
is also involved in glucose and lipid oxidation through its interaction with peroxisome 289 
proliferator-activated receptor α (PPARA) [34, 35]. PPARGC1A has also shown to be 290 
important for the transformation of muscle fibers to type I (slow-twitch, high levels of 291 
mitochondria) though binding with myocyte enhancer factor 2 (MEF2), which occurs as a 292 
result of the normal response of muscle tissue to endurance training, improving oxidative 293 
capacity and resistance to fatigue [36]. The importance of PPARGC1A is so manifold, 294 
through co-activation of differing pathways which all impact on the oxidative capacity of 295 
the skeletal muscles, that a single episode of extended endurance exercise can result in a 296 
7- to 10-fold increase in PPARGC1A expression peaking within two hours [34].  The 297 
functional polymorphism G482S, which is thought to interfere with PPARGC1A binding 298 
ability, has been shown to be strongly associated with performance, with a significantly 299 
lower frequency of the S allele in endurance athletes compared to both sedentary/unfit 300 
controls [34, 35] and sprint athletes [35], highlighting the endurance advantage conferred 301 
by the more common G allele. Though there is some evidence to suggest that the S allele 302 
impede mitochondrial biogenesis by decreasing activation of mitochondrial transcription 303 
factor TFAM, stronger evidence suggests that the S allele may interfere with muscle fiber 304 
transformation as the mutation is located within the MEF2-binding site of PPARGC1A 305 
and disrupts its binding [36]. This is further supported both by mouse studies, which 306 
show that PPARGC1A overexpression increases type I fiber ratio while knockout models 307 
show a decrease in type I and shift to type IIx and IIb fibers, and a recent study 308 
examining human muscle biopsies, which showed a lower level of post-training type I 309 
fibers in S carriers compared to G carriers, though mitochondrial density and activity, and 310 
intracellular lipid content was not different between different genotype groups [36]. 311 
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These data point to a clear advantage of G allele carriers in endurance performance and 312 
as such is an important component of any polygenic athletic profile. 313 
 314 
Materials and Methods 315 
Study population 316 
Ethical approval was obtained from the Human Research Ethics Committee 317 
(HREC) at Griffith University (Protocol No: MSC/06/05/HREC) and Queensland 318 
University of Technology (Approval number: 1300000499) and written consent was 319 
obtained from each participant. The study population consisted of a previously described 320 
[12] cohort of 196 elite endurance triathletes, whose selection as an “elite endurance 321 
athlete” was based on participation in the 2008 Ironman World Championship triathlon. 322 
This event involves a 3.8 km swim, 180 km bike ride, and 42.2 km marathon on the Kona 323 
coast of Hawaii [37]. Questionnaires were administered at the Kona Ironman event 324 
collecting data on a variety of demographic, health, and exercise-related variables, and 325 
approximately 1-2 ml saliva was collected for each participant using saliva collection kits 326 
(OG-250 Oragene Kit, DNA Genotek Inc.). DNA was extracted from saliva samples as 327 
described previously [12] and overall finishing time (referred to henceforth as 328 
performance time, or PT) was obtained from the official Kona 2008 Ironman results [38] 329 
for 173 of the 196 recruited participants. Eligibility criteria, methodology, and cohort 330 
characteristics are described in detail elsewhere [12]. 331 
 332 
Briefly, eligibility for the Kona Ironman championship is gained by earning a 333 
qualifying place in yearly qualifying half-Ironman or full-Ironman marathons run at 334 
differing locations worldwide. Approximately three-quarters of the participants were 335 
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male (N = 143, 73.0%) while about one-quarter were female (N = 53, 27.0%). Athletes 336 
originated from various countries from around the world, and were grouped according to 337 
continent of origin. Although 83.7% of athletes originated from North America (N = 104) 338 
or Europe (N = 60), although a small number did originate from Oceania (N = 23), South 339 
America (N = 6), Asia (N = 2) and Africa (N = 1). Most participants were between the 340 
ages of 30 and 50 (N = 123, 63.3%), with mean participant age 42.5 ± 11.4 yrs. Further 341 
detail on the cohort baseline characteristics and questionnaire data may be found in 342 
Grealy et al., 2013 [12].  343 
 344 
Genotyping assays 345 
Genotyping for the seven gene polymorphisms was performed by PCR 346 
amplification followed by various assays, including agarose gel electrophoreses (AGE), 347 
restriction fragment length polymorphism (RFLP) analysis, and high resolution melt 348 
(HRM) analysis (see Supporting Information Table S1 for primer sequences and assay 349 
details). Briefly, the ACE I/D polymorphism (287 bp Alu insertion, rs4340) was 350 
genotyped by PCR amplification using a previously published primer set [39] slightly 351 
adapted. The amplicon sizes for the deletion and insertion alleles were 182bp and 470bp 352 
respectively, allowing genotype discrimination after separation by AGE. The AMPD1 353 
Q12X polymorphism (C>T, rs17602729) was genotyped by PCR amplification using a 354 
previously published primer set [16] followed by restriction enzyme digestion with  355 
HpyCH4IV. The GDF8 K153R polymorphism (A>G, rs1805086),  the HFE H63D 356 
polymorphism (C>G, rs1799945), and the PPARGC1A G482S polymorphism (G>A, 357 
rs8192678) were all genotyped by PCR amplification using primer sets designed for this 358 
study, followed by restriction enzyme digestion with PspOMI, BclI, and MspI 359 
respectively. The ACTN3 R577X polymorphism (C>T, rs1815739) had been genotyped 360 
 16 
in this cohort previously [12]; data from this study was used for this multi-gene analysis. 361 
The genotyping method in the prior study was PCR amplification followed by HRM 362 
analysis. The CKMM NcoI 3’-untranslated region polymorphism (A>G, rs8111989) was 363 
genotyped by PCR amplification using a HRM primer set designed for this study, 364 
followed by HRM analysis. Positive controls for each genotype were created for each 365 
assay, and were genotyped using both the original assay and an alternative assay method 366 
such as sequencing or RFLP. Both typing methods resulted in 100% concordance of 367 
genotypes, for all assays. Positive controls were subsequently included in all genotyping 368 
runs on cohort samples. Additionally, HRM assays were genotyped in duplicate, with 369 
samples re-typed in cases of disagreement between duplicates. 370 
 371 
Statistical analysis 372 
Genotype frequencies were tested for conformation to Hardy-Weinberg 373 
Equilibrium (HWE), and compared to HapMap reference population frequencies using χ2 374 
tests or Fisher’s exact tests where appropriate. Performance time (PT) was analysed by 375 
one-way ANOVA tests to determine whether PT differed between genotype groups for 376 
individual polymorphisms in this cohort. PTs were also used to group the athletes into 377 
two extreme phenotypes, the top 10% performers (with fastest times) and the bottom 10% 378 
performers (with slowest times). Genotype frequencies in the top and bottom 10% groups 379 
were compared using Fisher’s exact tests. The combined effect of having multiple 380 
optimal alleles was assessed using the total genotype score procedure outlined previously 381 
[5]. Briefly, each genotype for a gene is scored as 0, 1, or 2, with the most optimal 382 
genotype for endurance scored as 2. For most of the markers, the scoring system by Ruiz 383 
et al. assumed an additive effect of an advantageous allele, with homozygotes of the non-384 
optimal allele assigned a score of 0 and heterozygotes with one copy of the optimal allele 385 
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assigned a score of 1. The only marker that did not fit this pattern was the HFE H63D 386 
polymorphism, in which H/D heterozygotes were scored as 2 while the H/H homozygote 387 
was scored as 0 and the D/D homozygote was scored as 1. This was due to the prior 388 
finding that heterozygotes are significantly overrepresented in endurance athletes versus 389 
controls [5, 31]. Genotype scores for each gene are summed to a total, divided by the 390 
maximum possible score (14 for 7 genes) and divided by 100 to yield a TGS for every 391 
individual. The distribution of TGS was plotted in the overall cohort and in the 10% 392 
fastest and 10% slowest race performers, and differences in TGS were analysed in these 393 
groups by t-test analysis. PT was modeled using linear regression with stepwise forward 394 
selection, to determine whether the TGS or any of the polymorphisms individually would 395 
be a significant factor in performance time, adjusting for the demographic variables age, 396 
sex, and continent of origin (shown to significantly influence performance time in our 397 
cohort previously [12]). Due to the heterogeneity in clinical characteristics (e.g. age, sex), 398 
lifestyle characteristics (e.g. smoking status), and fitness training characteristics (e.g. 399 
estimated number of exercise hours per week), demographic, health, and exercise-related 400 
data obtained from questionnaires (described previously in Grealy et al., 2013) were also 401 
examined for association with PT. 402 
 403 
Receiver operating characteristic (ROC) area under the curve (AUC) analyses 404 
were conducted to determine whether models with demographic and genetic variables 405 
could predict: (1) whether athlete performance time would be less than the median time; 406 
(2) whether athlete performance time would be less than the mean time; and (3) whether 407 
athletes would fall into the top 10% of performance times. Models included TGS only, 408 
demographic variables only, TGS and demographic variables, individual genes and 409 
demographic variables. The ROC curve is defined as a plot of test sensitivity or true 410 
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positive rate (TPR) as the y coordinate versus its specificity or false positive rate (FPR) 411 
as the x coordinate. It is an effective method to evaluate the quality or the performance of 412 
an diagnostic test [40]. The clinical performance of a laboratory test can be described in 413 
terms of diagnostic accuracy, or the ability to correctly classify subjects into clinically 414 
relevant sub-groups [41]. The most common way to quantify the diagnostic accuracy of a 415 
laboratory test is to measure the area under the ROC plot or AUC. The AUC value range 416 
between 1.0 (perfect separation of the test values of the two groups) and 0.5 (no apparent 417 
distributional difference between the two groups of test values) [40, 41]. All statistical 418 
analyses were conducted using the SPSS software (IBM SPSS v. 20.0 for Windows; IBM 419 
Corporation, Somers, NY) with an α level of 0.05.  420 
 421 
Results 422 
Genotyping success rate ranged from 99-100% for all markers except HFE 423 
(97.4% of samples successfully genotyped). The genotype distributions for all markers 424 
was found to conform with Hardy-Weinberg Equilibrium (HWE) in the overall cohort 425 
and in the subgroups of the 10% fastest and 10% slowest race performers (p > 0.05) for 426 
all groups and markers; see Supporting Information Table S2. Genotype frequencies for 427 
all Ironman athletes are shown in Table 1; these concorded well with reference 428 
frequencies derived from the HapMap CEU population (Utah residents with ancestry 429 
from Northern and Western Europe) [42] and were not significantly different for any 430 
marker except ACE rs4340. No data was available for ACE rs4340 in HapMap CEU 431 
population; data shown in Table 1 is drawn from Keavney et al. 2000, which is a UK 432 
study involving 5934 Caucasian myocardial infarction controls [43]. The Ironman cohort 433 
had a significantly higher frequency of the D/D genotype compared to this study 434 
(Ironman 42.3% D/D compared to 27.6%; χ2 p =1.68 x10-6).  Genotype distribution was 435 
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not significantly different in males and females, athletes from different continents, or 436 
athletes of different ages (see Supporting Information Table S3, Table S4, and Table S5); 437 
thus further analyses were undertaken without stratification by these groups. Genotype 438 
frequencies in the 10% fastest and 10% slowest race performers are also shown in Table 439 
1 and Figure 1; these were not significantly different for any marker, though this is most 440 
likely due to a lack of power as n = 17 for each group. There were non-significant trends 441 
observed in genotype distribution in top and bottom performers (see Supporting 442 
Information Figure S1), particularly  ACE, with a higher frequency of the I/I genotype in 443 
the top 10% performers (17.6% compared to 0.0%); for AMPD1, with a higher frequency 444 
of the Q/Q genotype in the top 10% performers (88.2% compared to 70.6%); and for 445 
CKMM, with a lower frequency of the G/G genotype in the top 10% performers (0.0% 446 
compared to 17.6%).  447 
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Table 1: Genotype frequency data in the Ironman athletes and the HapMap CEU reference population [42] 448 
aNumber of successfully genotyped samples per marker: ACE = 196 (100%); ACTN3 = 196 (100%); AMPD1 = 195 (99.5%); CKMM = 196 449 
(100%); GDF8 = 195 (99.5%); HFE = 191 (97.4%); PPARGC1A = 195 (99.5%).  bNo available data for ACE rs4340 in HapMap CEU 450 
population; data shown from Keavney et al. (2000) UK study involving 5934 Caucasian myocardial infarction controls [43]. cWhere a small 451 
number of observations prevented use of χ2, Fisher’s exact test was used.  452 
    Genotype frequency, n (%)  Genotype frequency, n (%)  
Gene rsID Markera Genotype HapMap CEU All athletes χ2  p Top 10% Bottom 10% Exact pc 
ACE rs4340 D/I D/D 1637b (27.6%) 83  (42.3%) 1.68 x10-6 5 (29.4%) 7 (41.2%) 0.278 
I/D 2980b (50.2%) 92   (46.9%)  9 (52.9%) 10 (58.8%)  
I/I 1317b (22.2%) 21   (10.7%)  3 (17.6%) 0 (0.0%)  
ACTN3 rs1815739 R577X R/R 22 (19.5%) 52  (26.5%) 0.29 5 (29.4%) 5 (29.4%) 1.000 
R/X 66 (58.4%) 98  (50.0%)  7 (41.2%) 8 (47.1%)  
X/X 25 (22.1%) 46  (23.5%)  5 (29.4%) 4 (23.5%)  
AMPD1 rs17602729 Q12X Q/Q 86 (76.1%) 149  (76.4%) 0.54c 15 (88.2%) 12 (70.6%) 0.398 
Q/X 24 (21.2%) 44   (22.6%)  2 (11.8%) 4 (23.5%)  
X/X 3 (2.7%) 2  (1.0%)  0 (0%) 1 (5.9%)  
CKMM rs8111989 3’ UTR   
NcoI RFLP 
A/A 58 (51.3%) 93  (47.4%) 0.32 9 (52.9%) 10 (58.8%) 0.156 
A/G 49 (43.4%) 83  (42.3%)  8 (47.1%) 4 (23.5%)  
G/G 6 (5.3%) 20  (10.2%)  0 (0.0%) 3 (17.6%)  
GDF8 rs1805086 K153R K/K 58 (96.7%) 186  (95.4%) 1.00c 17 (100.0%) 16 (94.1%) 1.000 
K/R 2 (3.3%) 9  (4.6%)  0 (0.0%) 1 (5.9%)  
R/R 0 (0.0%) 0  (0.0%)  0 (0.0%) 0 (0.0%)  
HFE rs1799945 H63D H/H 36 (64.3%) 138  (72.3%) 0.34c 13 (76.5%) 12 (75.0%) 1.000 
H/D 20 (35.7%) 51  (26.7%)  4 (23.5%) 4 (25.0%)  
D/D 0 (0.0%) 2  (1.0%)  0 (0.0%) 0 (0.0%)  
PPARGC1A rs8192678 G482S G/G 51 (45.1%) 74 (37.9%) 0.42 8 (47.1%) 7 (41.2%) 0.811 
G/S 45 (39.8%) 84  (43.1%)  7 (41.2%) 6 (35.3%)  
S/S 17 (15.1%) 37  (19.0%)  2 (11.8%) 4 (23.5%)  
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Figure 1: Distribution of genotypes in seven endurance related genes in the top and 453 
bottom 10% performers. 454 
 455 
Mean performance time (PT) overall was 11 hr 44.4 min ± 1 hr 51.4 min; the 456 
fastest finishing time was 9 hr 5.3 min, while the slowest finishing time was 16 hr 55.2 457 
min. Mean PTs and ANOVA comparisons for each genotype group are shown in Table 2. 458 
For each of the genes, the fastest PT was for:  ACE I/I genotype (685 min); ACTN3 R/R 459 
genotype (697 min); AMPD1 Q/Q genotype (704 min); CKMM A/G (695 min); GDF8 460 
K/R genotype (694 min); HFE D/D genotype (697 min); and PPARGC1A G/S genotype 461 
(704 min). For ACE and AMPD1, the fastest PT corresponded with the ‘optimal’ 462 
genotype for endurance. For CKMM, GDF8, PPARGC1A and HFE, the less optimal 463 
genotype had the fastest PT. Interestingly, for ACTN3, the fastest PT corresponded with 464 
the genotype optimally associated with speed/power (the R/R genotype), not endurance. 465 
For AMPD1, a trend of increasing mean PT for decreasing number of optimal alleles was 466 
observed; however, mean PT did not significantly differ between genotype groups for 467 
any of the individual polymorphisms in this cohort (p > 0.1). 468 
469 
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Table 2: Mean performance time (PT) in minutes within genotype groups 470 
 471 
Though these markers were not shown to be associated with being in the top 10% 472 
or significantly influence mean performance time individually, the combined effect of 473 
multiple optimal alleles was determined by calculating the TGS as per Ruiz et al. (2009), 474 
which is a percentage of optimal alleles obtained across all seven markers. In the total 475 
cohort of Ironman athletes, the mean ± SD of the TGS was 60.75 ± 12.95 (Fig. 2). The 476 
TGS ranged from a minimum score of 28.6 to 92.9,  with only two athletes having both 477 
the lowest and highest scores, and the distribution was both symmetrical (skewness 478 
statistic ± SE: -0.003 ± 0.18) and mesokurtic (kurtosis statistic ± SE: -0.230 ± 0.35). In 479 
Gene rsID Genotype n Mean PT (SE PT) F p Levene p 
ACE rs4340 D/D 75 704.6 (12.4) 0.655 0.521 0.304 
I/D 81 716.9 (13.2)    
I/I 17 684.9 (23.1)    
ACTN3 rs1815739 R/R 45 696.7 (16.4) 0.509 0.602 0.789 
R/X 85 716.7 (12.1)    
X/X 43 704.2 (17.2)    
AMPD1 rs17602729 Q/Q 132 704.4 (9.5) 1.805 0.168 0.240 
Q/X 38 716.9 (18.5)    
X/X 2 849.4 (166.4)    
CKMM rs8111989 A/A 83 717.3 (13.2) 0.954 0.387 0.144 
A/G 73 694.8 (11.2)    
G/G 17 723.0 (31.8)    
GDF8 rs1805086 K/K 164 709.6 (8.8) 0.148 0.701 0.262 
K/R 8 694.0 (32.7)    
R/R 0 - -    
HFE rs1799945 H/H 119 706.4 (10.3) 0.093 0.911 0.573 
H/D 47 714.2 (15.7)    
D/D 2 697.2 (50.8)    
PPARGC1A rs8192678 G/G 67 711.9 (14.2) 0.126 0.882 0.319 
G/S 72 703.9 (12.4)    
S/S 33 713.6 (20.7)    
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the top and bottom 10% performers (Fig. 3), the mean ± SD of the TGS was 65.1 ± 13.09 480 
and 58.9 ± 11.81, respectively (n=17 for top 10%; n=16 for bottom 10%). The TGS 481 
distribution was also symmetrical and mesokurtic in both the top 10% (skewness statistic 482 
± SE: -0.610 ± 0.55; kurtosis statistic ± SE: -0.734 ±1.06) and bottom 10% (skewness 483 
statistic ± SE: -0.354 ± 0.56; kurtosis statistic ± SE: -0.354 ± 1.09). The distribution in 484 
the top 10% was shifted to the right (towards higher TGS) compared to the bottom 10%. 485 
This difference was more clearly observed when TGS distribution was grouped into 10-486 
unit intervals (Fig. 4). Though mean TGS was smaller by ~6.2 units in the bottom 487 
performers compared with the top performers (or approximately one optimal allele fewer 488 
on average), this was not shown to be significant by t-test analysis   (t = 1.425, df = 31, p 489 
= 0.164).  490 
 491 
Figure 2. Frequency distribution of total genotype score (TGS) in overall Ironman 492 
cohort. 493 
 494 
Figure 3. Frequency distribution of total genotype score (TGS) in top and bottom 495 
10%. 496 
 497 
Figure 4. Frequency distribution of total genotype score (TGS) binned by 10-unit 498 
intervals. 499 
 500 
Performance time (PT) modelling using linear regression showed that clinical 501 
characteristics such as being a twin (n = 1), being a smoker (n = 1), and presence of a 502 
known disorder (n = 18) were not significantly associated with changes in PT. 503 
Occupational activity level and preferred exercise type were also shown to not 504 
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significantly influence PT. There was a significant trend of decreasing mean PT with 505 
increasing estimated weekly exercise hours, with mean PT ± SD of 761 ± 126 min for 506 
athletes exercising at least 3-8 hrs per week, 701 ± 109 min for weekly exercise at least 8-507 
12 hrs, and 682 ± 89 min for athletes exercising more than 12 hrs per week (F = 4.6, p = 508 
0.011). However, this effect was not significant when weekly exercise hours was 509 
included in the PT regression model with other variables (β = -47.7, p = 0.224). Only the 510 
demographic variables of age (β = 4.6, p = 7.782 x 10-12), sex (β = 76.9, p = 2.585 x 10-6), 511 
and continent of origin (β = -20.4, p = 0.008) were statistically significant, accounting for 512 
most of the variance in performance time (35.1%). Regression models of individual 513 
markers followed an additive genetic model adjusted for age, sex, and continent of origin; 514 
shown in Table 3. Only the AMPD1 marker was significantly associated with PT (model 515 
p = 5.79 x 10-17, AMPD1 genotype p = 0.01). Each AMPD1 null allele (non-optimal for 516 
endurance) resulted in an increase of about 39 minutes in PT, with X/X genotypes having 517 
an average increase of 78 min in PT compared to Q/X genotypes. The model accounted 518 
for 37.3% of the variance in PT, which was a significant improvement (F change = 6.99, 519 
p = 0.009) on the next best model of age, sex, and continent of origin alone (which 520 
accounted for 36.8% of the variance in performance). The regression model for total 521 
genotype score (Table 3) showed that TGS was not significantly associated with PT even 522 
when adjusted for age, sex, and continent of origin. The model with TGS accounted for 523 
only 34.4% of the variance in PT, which was not an improvement compared to a model 524 
with age, sex, and continent of origin alone (35.1%) or with the model of age, sex, and 525 
continent of origin with AMPD1 genotype (37.3%).   526 
 527 
Table 3: Regression models for performance time (adjusted for age, sex, continent) 528 
Gene N Model R Adjusted R2 Model F Model p Gene β Gene p 
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ACE 173 0.603 0.348 23.97 1.07 x 10-15 -5.86 0.581 
ACTN3 173 0.602 0.347 23.88 1.19 x 10-15  2.89 0.765 
AMPD1 172 0.622 0.373 26.38 5.79 x 10-17  38.71 0.010 
CKMM 173 0.607 0.353 24.46 5.82 x 10-16 -13.04 0.215 
GDF8 172 0.605 0.351 24.12 9.24 x 10-16 -5.47 0.867 
HFE 168 0.600 0.345 22.96 4.65 x 10-15 -13.45 0.353 
PPARGC1A 172 0.605 0.351 24.11 9.35 x 10-16  0.64 0.946 
TGS 168 0.600 0.344 22.86 5.22 x 10-15 -0.42 0.428 
 529 
Furthermore, ROC AUC analysis determined that TGS alone could not 530 
significantly predict whether an athlete would finish in (a) less than the median PT of 531 
681.33 min (AUC = 0.52, p = 0.674); (b) less than the mean PT of 708.39 min (AUC = 532 
0.48, p = 0.626); or (c) the top 10% fastest PT i.e. less than 593.7 min (AUC = 0.61, p = 533 
0.132). However, models with the demographic variables of age, sex, and continent of 534 
origin only, demographic variables and TGS, and demographic variables and AMPD1 535 
genotype were all found to significantly predict athlete finishing time for all three 536 
outcomes (less than median PT, less than mean PT, or in the top 10%). ROC AUC graphs 537 
for all analyses are shown in Fig. 5. The model with age, sex, continent and AMPD1 538 
genotype was found to be the most significant for predicting whether athletes would 539 
finish in less time than both the mean and median (Median AUC = 0.82, p = 8.92 x 10-13, 540 
95%CI = 0.75 to 0.88; Mean AUC = 0.81, p = 4.72 x 10-12, 95%CI = 0.75 to 0.87), while 541 
the model with age, sex, continent and TGS was the most significant model for predicting 542 
whether athletes would finish in the top 10% (AUC = 0.91, p = 3.50 x 10-8, 95%CI = 0.86 543 
to 0.96). However, the model with age, sex, continent, and AMPD1 genotype had similar 544 
though slightly less significant results (AUC = 0.90, p = 4.93 x 10-8, 95%CI = 0.85 to 545 
0.96). Of all the ROC AUC analyses (Fig. 5), the models for predicting top 10% finishers 546 
had the highest discrimination of performance in terms of sensitivity and specificity. The 547 
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point where sensitivity was maximized (sensitivity = 1.000) while minimizing the false 548 
positive rate and thus maximizing specificity (specificity = 0.742) corresponded to a 549 
model value of 672.28. Using the model equation PT = (4.65 • age) + (79.90 • sex) + (-550 
21.36 • continent) + (-0.42 • TGS) + 552.6, this would indicate that a North American 551 
male aged 35 yrs old would need a TGS of 51 or more in order to obtain the identified 552 
criteria cutoff of 672.28; however, a trade-off among the variables means that a lower 553 
TGS in combination with optimal values for the demographic variables would be equally 554 
likely to finish in the top 10%.  555 
 556 
Figure 5. Receiver operating characteristic curves (ROC) determining potential for 557 
PT prediction using four models.   558 
 559 
Discussion 560 
Overall, although expected genotype frequencies corresponded well with 561 
expected Caucasian frequencies from HapMap, none of the individual polymorphisms 562 
had significantly different genotype frequencies in the top and bottom 10% performers.  563 
This is perhaps due to power limitations, given that the top and bottom 10% of 564 
performers consisted of only seventeen individuals in each group for this study. However, 565 
none of the individual polymorphisms were found to significantly impact performance 566 
time when unadjusted for confounding demographic variables. Interestingly, an age-, sex- 567 
and continent of origin-adjusted analysis of AMPD1 Gln12Ter genotype showed a 568 
significant result, with the endurance-optimal Gln allele decreasing mean performance 569 
time.  570 
 571 
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As previously reported [12], age, sex, and continent of origin were extremely 572 
significant predictors of performance time and were included in all models to control for 573 
confounding effects. This is an extremely important additional step in any genetic 574 
analysis of endurance due to the heterogeneity of athletes performing at elite levels. Some 575 
studies have avoided the main confounders of ethnicity and sex by analysing subgroups 576 
(such as males) only [5]. This approach is useful for eliminating confounders but 577 
necessarily decreases the available pool of athletes for study and may result in lack of 578 
power. Additionally, age is rarely adjusted for in endurance case-control studies, which 579 
may be an important oversight given that age was the most highly significant variable in 580 
our analyses. This is even more important when the range of age of study participants can 581 
vary (as in analyses of professional athletes). Additionally, restricting analysis by ethnic 582 
group may not remove all of the confounding present in country or continent of origin; 583 
we found a significant effect for continent of origin. This is unlikely to be due to 584 
confounding from continent-specific genetic effects as only small sample sizes were 585 
obtained from South America, Africa, and Asia, and may instead reflect continent-586 
specific socio-economic factors relating to training availability or training type.  587 
 588 
Indeed, training variables are an additional important factor to account for in such 589 
studies, as different training types and durations can have hugely significant impacts on 590 
athlete capabilities. In this study, fitness training characteristics were determined only 591 
through estimated weekly exercise hours (determined by exercise frequency and duration 592 
questions). However, this data alone cannot meaningfully inform the effect of athlete 593 
training on performance, as even low volume exercise may potently increase athlete 594 
endurance performance for certain training types, such as high-intensity interval training 595 
(HIT). For instance, muscle mitochondrial capacity, resting muscle glycogen, and 596 
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GLUT4 protein content were all found to be improved significantly by HIT in a 2010 597 
study, despite the fact that the training was merely six training sessions of 8-12 x 60 598 
second intervals (with interspersed 75-second recovery periods)[44]. Furthermore, this 599 
study showed significant decreases in time to complete 50kJ and 750kJ cycling time trials 600 
with significant increases in mean power output also[44]. The benefits of HIT have even 601 
been observed for sedentary and middle-aged individuals, which obtains the health 602 
advantages of traditional endurance training with only a small time commitment[45]. 603 
Thus, explicit recording of training type, as well as training volume, are vitally important 604 
for future analyses of endurance performance.  605 
 606 
These findings highlight the importance of including potentially confounding 607 
environmental factors in genetic analyses of athletic performance. This should not be 608 
surprising, given that while endurance endophenotypes have been shown to have high 609 
heritabilities (h2 = 40-60%) and while athletic status itself has also been reported to be 610 
highly heritable (h2 >50%) [4], non-genetic environmental factors must still contribute at 611 
least half of the variance in endurance phenotype. This can be due to both shared 612 
environment (such as the training provided to national-level athletes for a specific 613 
country) and non-shared environment (individual efforts in training sessions, frequency 614 
and duration of training sessions, etc.). As genetic analyses show that each allele must 615 
contribute relatively small amounts of variance to the overall phenotype compared with 616 
environmental factors [46], these types of variables should be consistently accounted for 617 
in order to prevent masking of significant genetic effects, such as we observed for 618 
AMPD1 Gln12Ter.  619 
 620 
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Another method of preventing polymorphisms with individual small effect from 621 
escaping statistical detection is to analyse their joint effects using the TGS system. This 622 
has been used to successfully show a significant difference in genetic profile 623 
‘favourability’ between endurance athletes versus non-athlete controls for the seven-gene 624 
endurance profile [5] or a ten-gene endurance profile [4], endurance athletes and non-625 
athlete controls versus power athletes for a six-gene power profile [6], and endurance 626 
athletes versus power athletes and non-athlete control for a six-gene mitochondrial 627 
biogenesis endurance profile [10]. However, although the TGS distribution for our 628 
Ironman athletes (mean 60.75 ± std. dev. 12.95) was comparable to the distribution of 629 
TGS of Spanish non-athletic controls described in Ruiz et al. 2009 (mean 62.43 ± std. 630 
dev. 11.45), the TGS distribution in the Ironman athletes was overall lower than for 631 
Spanish endurance athletes (mean 70.22 ± std. dev. 15.58). Similar to the reported results 632 
in Spanish endurance athletes by Ruiz et al. 2009, we observed multiple ‘peaks’ in the 633 
distribution of the endurance athletes. The first peak was observed at a TGS ~43 and was 634 
common to both top and bottom performers; the second peak was observed at a TGS of 635 
~57 for the bottom 10% but ~64 for the top 10%; a possible third peak was observed for 636 
top 10% performers at TGS of ~79. The difference in frequency of higher TGS for top 637 
performers compared with lower TGS for bottom performers was more clearly observed 638 
when TGS distribution was grouped into 10-unit intervals. This might suggest that there 639 
groupings of optimal alleles, perhaps, the likelihood of an optimal allele for one marker 640 
increases the likelihood of having other optimal alleles (and vice versa). Thus far, this 641 
possibility has not been explored in relation to the TGS, as what all the currently existing 642 
TGS models have in common is that they represent the proportion or percentage of 643 
‘optimal’ alleles for a particular phenotype, and assumes an additive genetic model of 644 
allele favourability for all polymorphism except HFE (where the heterozygote is 645 
 30 
considered ‘most optimal’). Furthermore, the TGS follows a simple additive model of 646 
athletic advantage between different polymorphisms, which may not be the case if gene-647 
gene and gene-environment interactions result in non-additive advantages for certain 648 
allele combinations. Several papers have already reported gene-gene interactions for 649 
small combinations of genes [4, 47, 48]; of particular interest is that performance time of 650 
South African Ironman triathletes was significantly influenced by the interaction of the 651 
NOS3 and BDKRB2 genes (individuals with the NOS3 GG genotype + BDKRB2 19 allele 652 
were significantly slower than other combinations) [48]. More sophisticated TGS models 653 
taking such interactions into account may be necessary to accurately model genetic 654 
advantages for performance; however it is also clear that currently information on gene-655 
gene interactions and gene-environment interactions for these genes are lacking [46]. It is 656 
also important to realise that any TGS model which accounts for gene-gene or gene-657 
environment will become additionally complex. The power to perform such analyses may 658 
also be lacking, given that sample size has typically been an issue for elite performance 659 
studies [46, 49]. 660 
 661 
These reasons may also partly explain why TGS was not significantly associated 662 
with PT in our cohort even when adjusted for age, sex, and origin and that ROC AUC 663 
analysis determined that TGS alone could not significantly predict whether an athlete 664 
would finish in less than the median or mean or the top 10% fastest PT. Alternatively, the 665 
TGS profile for ‘optimal endurance’ may not be an appropriate profile for examining 666 
event performance as an outcome, even an endurance event. Additionally, even differing 667 
types of endurance events may show different levels of association with ‘endurance’ 668 
genes; while acknowledged as one of the most gruelling endurance events in the world, 669 
the Ironman championships require a blend of cycling, running, and swimming skills, 670 
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which makes them more of a complex phenotype than single-sport endurance events such 671 
as running. Triathlons may thus require different set of ‘optimal alleles’, emphasising not 672 
only endurance-associated genes but perhaps power-associated as well. “Success” in any 673 
kind of endurance event relies, in addition to endurance capabilities, on speed and 674 
strength to outperform competitors.  675 
 676 
Thus, in the TGS profile we employed, the ACTN3 Arg577Ter null allele (X) was 677 
coded as the ‘optimal’ endurance allele and the X/X genotype was given a genotype score 678 
of 2, the R/X genotype given a score of 1, and the R/R genotype given a score of 0. 679 
However, the R allele is highly associated with speed and power [6], and the presence of 680 
an R allele may give an endurance event competitor an edge over an athlete with 681 
homozygous X/X genotype. In fact, Ruiz et al.’s 2010 speed/power profile showed three 682 
common polymorphisms to the endurance profile (ACE Ins/Del, ACTN3 Arg577Ter, and 683 
GDF8 Lys153Arg), albeit with inverse allele coding [6]. Thus, 3 out of the 14 684 
polymorphisms used in our TGS calculation may in fact be more suitable with the power 685 
allele coded as the ‘optimal’ allele. An alternative profile for performance time may need 686 
to be investigated in order to determine a model that will predict athlete finishing time 687 
with discriminating sensitivity and specificity. Such as model may be useful in assisting 688 
with athletic training as well as helping athletes understand what factors underlie their 689 
performance, by allowing athletes to pinpoint factors to work on in order to improve 690 
performance time, as well as personalize their training to their optimal genetic profile. 691 
Before this can be done, however, more sophisticated genetic models should be 692 
investigated to ensure that the additive model is not masking gene-gene or gene-693 
environment interactions; non-genetic factors such as training methods and duration 694 
should be recorded and included in future genetic analyses to prevent confounding; and 695 
 32 
large collaborations should be undertaken to obtain sufficient sample sizes for powerful 696 
and complex analyses of endurance performance. 697 
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